5 results
6-K
EX-99.1
LEGN
Legend Biotech Corp
11 Dec 23
Legend Biotech Corporation 6-K
7:32pm
in the SOC arm (hazard ratio [HR], 0.42), as measured with the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q; 5-point scale).1
CARTITUDE-4
6-K
EX-99.1
LEGN
Legend Biotech Corp
5 Jun 23
Legend Biotech 6-K
11:17am
improvement in progression-free survival, with a hazard ratio of 0.26
CARTITUDE-4 is the first randomized study investigating the efficacy of a cell therapy … lines of therapy and are refractory to lenalidomide (Hazard ratio [HR]=0.26 (95% CI, 0.18–0.38); P-value [P] <0.0001).1 The study data were featured
6-K
EX-99.1
LEGN
Legend Biotech Corp
21 Apr 23
Legend Biotech Corporation 6-K
8:30am
by 74% (Hazard ratio [HR]=0.26; P-value [P] <0.0001). Patients in the cilta-cel group had significantly improved overall response rate, rate
- Prev
- 1
- Next